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Abstract
Background and Objective Little is known about acetaminophen (paracetamol) pharmacokinetics during pregnancy. The 
aim of this study was to develop a physiologically based pharmacokinetic (PBPK) model to predict acetaminophen phar-
macokinetics throughout pregnancy.
Methods PBPK models for acetaminophen and its metabolites were developed in non-pregnant and pregnant women. Physi-
ological and enzymatic changes in pregnant women expected to impact acetaminophen pharmacokinetics were considered. 
Models were evaluated using goodness-of-fit plots and by comparing predicted pharmacokinetic profiles with in vivo phar-
macokinetic data. Predictions were performed to illustrate the average concentration at steady state (Css,avg) values, used 
as an indicator for efficacy, of acetaminophen achieved following administration of 1000 mg every 6 h. Furthermore, as a 
measurement of potential hepatotoxicity, the molar dose fraction of acetaminophen converted to N-acetyl-p-benzoquinone 
imine (NAPQI) was estimated.
Results PBPK models successfully predicted the pharmacokinetics of acetaminophen and its metabolites in non-pregnant 
and pregnant women. Predictions resulted in the lowest Css,avg in the third trimester (median [interquartile range]: 4.5 
[3.8–5.1] mg/L), while Css,avg was 6.7 [5.9–7.4], 5.6 [4.7–6.3], and 4.9 [4.1–5.5] mg/L in non-pregnant, first trimester, and 
second trimester populations, respectively. Assuming a constant raised cytochrome P450 2E1 activity throughout pregnancy, 
the molar dose fraction of acetaminophen converted to NAPQI was highest during the first trimester (median [interquartile 
range]: 11.0% [9.1–13.4%]), followed by the second (9.0% [7.5–11.0%]) and third trimester (8.2% [6.8–10.1%]), compared 
with non-pregnant women (7.7% [6.4–9.4%]).
Conclusion Acetaminophen exposure is lower in pregnant than in non-pregnant women, and is related to pregnancy dura-
tion. Despite these findings, higher dose adjustments cannot be advised yet as it is unknown whether pregnancy affects the 
toxicodynamics of NAPQI. Information on glutathione abundance during pregnancy and NAPQI in vivo data are required 
to further refine the presented model.
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1 Introduction
Pregnancy is associated with physiological changes that 
might affect the pharmacokinetics of many drugs [1]. If 
pregnant women are administered the same dose as non-
pregnant women, potential pharmacokinetic changes may 
lead to either sub-therapeutic or toxic drug effects in the 
mother and/or fetus [2]. Since pregnant women are consid-
erably underrepresented in clinical trials, information on 
optimal dosing during pregnancy is widely lacking [3]. As 
a result, because a quantitative and mechanistic understand-
ing of pharmacokinetic alterations during pregnancy is often 
missing, determining of an appropriate dose is difficult [4]. 
Physiologically based pharmacokinetic (PBPK) modeling 
is considered a valuable tool for predicting pharmacokinetic 
changes throughout pregnancy and can be used to investigate 
pharmacokinetics and support dosing strategies [5]. PBPK 
models are multi-compartment models that mechanisti-
cally describe the processes of drug liberation, absorption, 
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Key Points 
Simulations following administration of acetaminophen 
(paracetamol) 1000 mg every 6 h to both non-pregnant 
and pregnant women showed that the acetaminophen 
average concentration at steady state (Css,avg), was lowest 
in the third trimester (median: 4.5 mg/L), while Css,avg 
was 6.7 [5.9–7.4], 5.6, and 4.9 mg/L in non-pregnant, 
first trimester, and second trimester populations, respec-
tively.
Assuming a constant raised activity of cytochrome P450 
2E1 throughout pregnancy, the median dose fraction 
of acetaminophen converted to the reactive metabolite 
N-acetyl-p-benzoquinone imine (NAPQI) was predicted 
to be 7.7%, 11.0%, 9.0%, and 8.2% in non-pregnant, first, 
second and third trimester populations, respectively.
To better characterize the hepatotoxic risk of acetami-
nophen throughout these different stages of pregnancy, 
further investigations into NAPQI formation during 
different stages of pregnancy need to be combined with 
an assessment of potential changes in the detoxifying 
capacity (e.g., glutathione levels) of non-pregnant and 
pregnant women.
covalently to cellular proteins, thereby forming toxic protein 
adducts. This leads to mitochondrial dysfunction and early 
oxidative stress, which can ultimately result in hepatocellular 
necrosis [10, 11].
Due to limited data on acetaminophen pharmacokinetics 
in pregnant women, the main objective of this study was 
to develop a pregnancy PBPK model that can be used to 
(1) predict maternal pharmacokinetics of acetaminophen 
and its metabolites in pregnant women at delivery; and (2) 
extrapolate the pharmacokinetics of acetaminophen and its 
metabolites to earlier stages of pregnancy in order to com-
pare the acetaminophen average concentration at steady state 
(Css,avg) and NAPQI formation, as a marker for efficacy and 
potential hepatotoxicity, respectively, to those in non-preg-
nant women.
2  Materials and Methods
2.1  Software
All PBPK models were built in PK-Sim® and  MoBi® version 
7.2.0 software, both part of the Open Systems Pharmacol-
ogy Suite. All source codes and the herein developed mod-
els are publicly available on GitHub (accessible via http://
www.open-syste ms-pharm acolo gy.org). Reference PBPK 
models for adults were developed in PK-Sim®. The preg-
nancy PBPK models were built in  MoBi® and subsequently 
exported to PK-Sim® for population simulations. WebPlot-
Digitizer (http://autom eris.io/WebPl otDig itize r/) was used to 
extract data from published figures and digitize them. R (ver-
sion 3.3.0) was used together with RStudio (version 1.1.453) 
for graphics creation and statistical analysis.
2.2  General Workflow
The workflow for constructing and translating a PBPK model 
to pregnant women (Fig. 1) has recently been described [12] 
and is summarized here, as it is relevant to this analysis. 
PBPK models for acetaminophen were developed for a non-
pregnant population for IV administration and then, keeping 
distribution- and clearance-related parameters unchanged, 
for oral administration [13]. The demographic measures 
of the virtual subjects matched those of the in vivo study 
group, if the latter were reported. The non-pregnant PBPK 
model incorporated the PK-Sim® standard model structure 
comprising 18 compartments [14]. The model was evalu-
ated by comparing the pharmacokinetic simulation with 
observed in vivo pharmacokinetic data taken from litera-
ture. If needed, drug-specific parameters were refined in 
the non-pregnant model by fitting the simulated plasma 
concentration–time curve to the observed data using Monte 
distribution, metabolism, and excretion through a set of dif-
ferential equations [6].
Acetaminophen (paracetamol) is one of the most com-
monly used drugs during pregnancy [7]. Oral acetaminophen 
is used to treat mild to moderate pain and fever during preg-
nancy, while intravenous (IV) acetaminophen serves as 
an analgesic in the immediate postoperative period, e.g., 
after cesarean delivery [8]. Acetaminophen is eliminated 
through various metabolic pathways [9]. In non-pregnant 
healthy women, it is mainly metabolized to acetaminophen 
glucuronide via different uridine 5′-diphospho-glucurono-
syltransferase (UGT) isoforms and to acetaminophen sulfate 
through sulfotransferases (SULT). In addition, it is metabo-
lized by several cytochrome P450 (CYP) enzymes, primar-
ily by CYP2E1, to the reactive (and therefore potentially 
toxic) metabolite N-acetyl-p-benzoquinone imine (NAPQI), 
and a small fraction is also excreted as unchanged drug in 
urine [10]. Under normal conditions, NAPQI is immediately 
detoxified by conjugation with glutathione. The glutathione 
conjugate is further metabolized to cysteine and mercap-
turate derivatives of acetaminophen [9]. At high doses, 
however, glutathione becomes depleted and NAPQI binds 
PBPK Modeling of Acetaminophen in Non-pregnant and Pregnant Women
Carlo algorithm implemented in the software’s Parameter 
Identification toolbox. Thereafter, all drug-specific param-
eters, except the fraction unbound (fu), were fixed and the 
model was extrapolated to pregnant women by substitut-
ing the standard model structure with the pregnancy model 
structure, which includes nine additional compartments 
[2, 12]. Pharmacokinetic predictions were performed in a 
population of pregnant women that matched anthropometric 
measures of the in vivo study group of pregnant women. 
If not reported, the mean gestational age-specific demo-
graphic measures available in PK-Sim® were used. Finally, 
pharmacokinetic predictions were evaluated by comparing 
the results with in vivo pharmacokinetic data taken from 
literature.
2.3  Development of Physiologically Based 
Pharmacokinetic (PBPK) Models 
for Acetaminophen
A detailed overview of the development of PBPK models 
for acetaminophen is provided in the Electronic Supple-
mentary Material (ESM_1). Input data used in the PBPK 
models are listed in Table 1. Briefly, acetaminophen was 
loaded from a template provided with the software that also 
includes a parameterization of the main metabolic pathways 
of both acetaminophen and its main metabolites. Of note, 
due to missing literature information, it was assumed in this 
template that the concentration of cysteine and mercaptur-
ate is equivalent to that of NAPQI [14]. Characteristics of 
Fig. 1  Schematic workflow 
of pregnancy physiologically 
based pharmacokinetic model 
development and validation. 
Css,avg average concentration 
at steady state, IV intravenous, 
NAPQI N-acetyl-p-benzoqui-
none imine, PBPK physiologi-
cally based pharmacokinetic, 
phys-chem physicochemical, PK 
pharmacokinetic
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comparison studies providing in vivo pharmacokinetic data 
are detailed in Table 2. 
2.4  Enzymatic Changes During Pregnancy
The focus of this study was to predict maternal disposition 
of acetaminophen metabolized via UGT1A1, SULT1A1, 
and CYP2E1 and to quantify the fractional (molar acetami-
nophen) clearance via each of these pathways. Therefore, 
the literature was screened for quantitative information on 
pregnancy-related changes in the expression and activity of 
these enzymes.
2.4.1  Uridine 5′‑Diphospho‑Glucuronosyltransferase 
(UGT) 1A1
Literature data that allow informing the PBPK model 
with changes in UGT1A1 expression during human preg-
nancy are scarce. The approach used here relied on in vivo 
serum concentrations of bilirubin, an exclusive substrate of 
Table 1  Summary of input data for the physiologically based pharmacokinetic models for acetaminophen and its metabolites, as implemented in 
the PK-Sim® template [14]
CYP cytochrome P450, fe dose fraction excreted unchanged in urine, fm dose fraction metabolized via a specific enzymatic pathway, GFR glo-
merular filtration rate, Km Michaelis-Menten constant, NA not applicable, NAPQI N-acetyl-p-benzoquinone imine, pKa acid dissociation con-
stant, RT-PCR reverse transcription polymerase chain reaction, SULT sulfotransferase, UGT uridine 5ʹ-diphospho-glucuronosyltransferase, Vmax 
maximal velocity
a Values simultaneously fitted to in vivo pharmacokinetic data of non-pregnant subjects [33, 34] and to the contribution of each biotransformation 
pathway to overall elimination [19–22]
b The implemented value in the template (1.25 log units) was found to be associated with an underestimation of observed plasma concentrations 
in the early distribution phase and was hence optimized
Parameter [unit] Acetaminophen Acetaminophen glucuronide Acetaminophen sulfate NAPQI
Molecular weight [g/mol] 151 327 231 149
Lipophilicity [log units] 1.11a,b − 1.0 − 1.0 0.53
pKa (acid) 9.41 3.17 2.2 NA
Fraction unbound 0.82 0.92 0.46 0.26
Major binding protein Albumin Unknown Unknown Albumin
Solubility (pH 7) [mg/mL] 17.3 20.8 1.54 0.987
Weibull 50% dissolution time [min] 10.50a NA NA NA
Intestinal permeability (transcellular) [cm/
min]
9.62 × 10−5 a NA NA NA
Model for estimating organ-to-plasma parti-
tion coefficients
Rodgers & Rowland Rodgers & Rowland Rodgers & Rowland Rodgers & Rowland
Metabolic clearance parameters
 Specific intrinsic clearance via CYP2E1 
[mL/min per mL tissue]
5.72 × 10−3 a NA NA NA
 Km, UGT1A1 [µmol/L] 462a NA NA NA
 Vmax, UGT1A1 [µmol/L/min] 49.0a NA NA NA
 Km, SULT1A1 [µmol/L] 115a NA NA NA
 Vmax, SULT1A1 [µmol/L/min] 9.62a NA NA NA
 Expression profiles for enzymes RT-PCR NA NA NA
Renal clearance parameters
 Specific tubular secretion following linear 
kinetics [mL/min per mL tissue]
NA 0.352 NA NA
 Km [µmol/L] NA NA 41.4 NA
 Vmax [µmol/L/min] NA NA 82.9 NA
 GFR fraction 0.32 NA NA 1
Dose fractions excreted unchanged in urine (fe) and metabolized (fm) via different enzymes:
 fm, CYP2E1 0.08 NA NA NA
 fm, UGT1A1 0.58 NA NA NA
 fm, SULT1A1 0.30 NA NA NA
 fe 0.04 1 1 1
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UGT1A1 [15]. In a cohort of 103 healthy pregnant women, 
the mean serum concentrations of free bilirubin were 25%, 
43%, and 48% lower in the first, second, and third trimester, 
respectively, than the mean value in non-pregnant women 
[16]. From these figures, the fold increases in bilirubin clear-
ance, a surrogate for UGT1A1 induction, were estimated to 
be 1.33, 1.75, and 1.92 in the first, second, and third trimes-
ter, respectively.
2.4.2  Sulfotransferase (SULT) 1A1
In human endometrial tissue, SULT1A1 activity in early 
pregnancy (10 weeks of gestational age), as assessed by the 
clearance of probe drugs, did not differ from that in non-
pregnant subjects. Furthermore, expression of SULT1A1 
was unaffected by progesterone [17]. In rat experiments, 
hepatic SULT1A1 expression was not substantially influ-
enced by estradiol or progesterone [18]. Thus, no change in 
SULT1A1 expression throughout pregnancy was assumed.
2.4.3  Cytochrome P450 (CYP) 2E1
Due to conflicting data [19, 20] (see Sect. 4), it was not pos-
sible to quantitatively estimate pregnancy-induced changes 
in CYP2E1 with high certainty. Studying peripartum women 
5 min after delivery, Kulo et al. [21] found a 1.8-fold higher 
clearance of acetaminophen to oxidative metabolites than in 
12 weeks postpartum women; this finding was supported by 
Miners et al. [22]. As CYP2E1 is the major enzyme involved 
in acetaminophen oxidation, and since this study aims to 
predict exposure to NAPQI with as little uncertainty as pos-
sible, the value reported by Kulo et al. [21] was used here 
[23]. For earlier stages of pregnancy, the same increase was 
assumed. Although at earlier stages of pregnancy a lower 
value may be physiologically plausible, an 80% induc-
tion was used here because this value translates into the 
maximum NAPQI formation clearance that can probably 
be expected in vivo and thus represents the upper range of 
potential NAPQI formation during pregnancy (‘worst-case 
scenario’).
2.5  Statistical Analysis
The pharmacokinetics of acetaminophen were simulated in 
a population of 2000 virtual individuals following an oral 
administration dosing regimen of 1000 mg every 6 h for 
48 h. The molar dose fractions of acetaminophen undergoing 
metabolism to its metabolites (acetaminophen glucuronide, 
acetaminophen sulfate, and NAPQI) were calculated. In 
addition, for each simulated or predicted concentration–time 
profile, the molar area under the plasma concentration–time 
curve (AUC) of acetaminophen, acetaminophen glucuron-
ide, acetaminophen sulfate, and NAPQI was calculated. Ta
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After this, the ratio of the AUC of the metabolite to that of 
acetaminophen (AUC ratio) was calculated. The molar dose 
fraction of acetaminophen converted to NAPQI as well as 
the molar AUC ratio of NAPQI/acetaminophen were used as 
surrogate markers for potential hepatotoxicity. Based on the 
AUC of acetaminophen, the Css,avg was calculated, in both 
non-pregnant and pregnant women, as Css,avg is a widely 
used measurement to assess acetaminophen efficacy [24].
2.6  Model Evaluation
Simulated and predicted pharmacokinetic profiles were 
compared with the observed in vivo data (Table 2). Addi-
tionally, ratios of predicted to observed mean pharmacoki-
netic parameters were calculated. Finally, pharmacokinetic 
simulations and predictions were evaluated with the use of 
goodness-of-fit plots, depicting observed versus simulated 
or predicted plasma concentrations. A sensitivity analysis 
was performed on CYP2E1 expression, ranging from 0 to 
160% induction, to evaluate the impact of different CYP2E1 
expression patterns on the pharmacokinetics of acetami-
nophen and NAPQI during the first trimester of pregnancy. 
A sensitivity analysis on CYP2E1 expression in the first tri-
mester was performed as highest uncertainty was assumed 
in the model during this trimester due to an absolute lack of 
CYP2E1 expression patterns.
3  Results
3.1  PBPK Models for Acetaminophen
The plasma concentration–time profile of acetaminophen 
simulated in populations of non-pregnant women was in 
good agreement with in vivo pharmacokinetic data (Figs. 2a, 
3a). All simulated mean plasma concentrations of acetami-
nophen after both oral and IV administration fell within a 
2-fold error range (Fig. 4). In vivo urine data after IV admin-
istration in non-pregnant women were available for acetami-
nophen glucuronide, acetaminophen sulfate, and unchanged 
acetaminophen and are depicted in Fig. 3a. This resulted in 
adequate predictions of acetaminophen excreted unchanged 
in urine (Figs. 3a, 4). For the two major metabolites, glucu-
ronide and sulfate, the model slightly underestimated urine 
concentrations (Figs. 3a, 4). Due to lack of NAPQI in vivo 
data, simulations of NAPQI plasma concentrations could not 
be evaluated. As indicated in Table 3, all simulated pharma-
cokinetic parameters in non-pregnant women fell well within 
a 1.5-fold error range. Ratios of simulated to observed phar-
macokinetic parameters were not estimated for the metabo-
lites in non-pregnant women after IV administration, as only 
one sample per patient was available. Overall, these PBPK 
models were deemed adequate and used for translation to 
pregnancy.
After translation to pregnancy, the predicted plasma con-
centration–time profile of IV-administered acetaminophen 
in populations of pregnant women at delivery was in good 
agreement with the observed data (Fig. 3b). In vivo urine 
data at delivery were available for acetaminophen glucuro-
nide, acetaminophen sulfate, and unchanged acetaminophen 
and are depicted in Fig. 3b. Concerning acetaminophen 
sulfate and unchanged acetaminophen in urine at delivery, 
one predicted mean plasma concentration was within the 
2-fold error range, while the other one was outside. As for 
acetaminophen glucuronide, renal excretion appeared to be 
generally over predicted. Thereafter, the model was extrapo-
lated to earlier stages of pregnancy. Figure 2b shows a good 
Fig. 2  Median predicted (purple) and observed [33] (white dots) 
acetaminophen plasma concentration–time profiles in populations 
of a non-pregnant women and b first trimester pregnant women 
after administration of oral acetaminophen 650 mg. The shaded area 
denotes the predicted 95% confidence interval. The error bars denote 
the standard deviations of the observed data. NAPQI N-acetyl-p-ben-
zoquinone imine
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agreement between the predicted plasma concentration–time 
profile of acetaminophen in the first trimester of pregnancy 
after oral administration and the observed pharmacokinetic 
data. All simulated mean plasma concentrations of aceta-
minophen after both oral and IV administration fell within 
a 2-fold error range (Figs. 2, 3b, 4). Again due to a lack of 
NAPQI in vivo data, predictions of NAPQI plasma concen-
trations could not be evaluated. As indicated in Table 3, all 
predicted pharmacokinetic parameters of acetaminophen 
throughout pregnancy fell well within a 1.5-fold error 
range. The ratio of predicted to observed pharmacokinetic 
parameters was not estimated for the metabolites in pregnant 
women at term after IV administration, since only two sam-
ples per patient were available.
Regarding the plasma concentration–time profiles of 
oral acetaminophen 1000 mg in non-pregnant and pregnant 
populations (ESM_2A), maximum concentration (Cmax) 
values were higher in non-pregnant women and decreased 
with increasing duration of gestational week, while the AUC 
from time zero to 6 h (AUC 0-6h) decreased with increasing 
duration of gestational age. Regarding the plasma concen-
tration–time profiles of NAPQI after administration of oral 
Fig. 3  Median predicted and observed [31] acetaminophen plasma 
concentration–time profiles (left) and predicted and observed [31] 
acetaminophen inactive metabolites urine concentration–time profiles 
(right) in populations of a non-pregnant women after administration 
of intravenous acetaminophen 2000  mg and b third trimester preg-
nant women after administration of an intravenous acetaminophen 
2000 mg loading dose followed by 1000 mg every 6 h. For the inac-
tive metabolites, orange, pink, and green indicate acetaminophen 
glucuronide, acetaminophen sulfate, and unchanged acetaminophen 
in urine concentrations, respectively. The shaded area denotes the 
predicted 95% confidence interval. NAPQI N-acetyl-p-benzoquinone 
imine
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acetaminophen 1000 mg in both the non-pregnant and preg-
nant women (ESM_2B), the highest Cmax and AUC 0-6h were 
predicted during the first trimester of pregnancy.
The sensitivity analysis (ESM_3) revealed that changes 
in CYP2E1 expression substantially impact the simulated 
NAPQI plasma concentration, while the effect on the aceta-
minophen concentration is insignificant.
3.1.1  Acetaminophen Average Concentration at Steady 
State and Acetyl‑p‑Benzoquinone Imine (NAPQI) 
Exposure
Following oral administration of acetaminophen 1000 mg, 
the predicted Css,avg (median [interquartile range, IQR]) was 
6.7 [5.9–7.4], 5.6 [4.6–6.3], 4.9 [4.1–5.5], and 4.5 [3.8–5.1] 
Fig. 4  Goodness-of-fit plot (predicted concentration versus observed 
concentration) for acetaminophen and its metabolites (acetaminophen 
unchanged, acetaminophen glucuronide, acetaminophen sulfate). For 
non-pregnant women, observed acetaminophen data were taken from 
Allegaert et  al. [31], Mitchell et  al. [34], and Beaulac-Baillargeon 
and Rocheleau [33]; for pregnant women, observed acetaminophen, 
acetaminophen glucuronide, and acetaminophen sulfate data were 
taken from Allegaert et al. [31] and Beaulac-Baillargeon and Roche-
leau [33]. The solid line denotes the line of identity. The dotted lines 
denote the 2-fold error range. APAP acetaminophen, conc concen-
tration, GLUC glucuronide, NP non-pregnant, P1 first trimester, P3 
third trimester, SULF sulfate, U unchanged
Table 3  Comparison between 
observed and simulated or 
predicted pharmacokinetic 
parameters of acetaminophen in 
both non-pregnant and pregnant 
women
Observed PK parameters for acetaminophen for both non-pregnant and pregnant women following oral 
administration of 650  mg are taken from Beaulac-Baillargeon and Rocheleau [33] and those following 
intravenous administration of 2000 mg from Allegaert et al. [31]. Data are expressed as mean
AUC ∞ area under the plasma concentration–time curve from time zero to infinity, CL clearance, Cmax maxi-
mum concentration, F bioavailability, PK pharmacokinetic, Vd volume of distribution
Study PK parameter (unit) Non-pregnant women Pregnant women
Observed Simulated Ratio Observed Predicted Ratio
Beaulac-Baillargeon 
and Rocheleau 
[33]
AUC ∞ (mg*h/L) 24.45 35.34 1.44 18.59 23.95 1.28
CL/F (L/h) 18.53 18.39 0.99 26.50 27.14 1.02
Vd/F (L) 58.85 52.47 0.89 66.25 62.75 0.95
Cmax (mg/L) 9.92 9.17 0.92 9.80 7.90 0.81
Allegaert et al. [31] AUC ∞ (mg*h/L) 101.71 106.12 1.04 74.30 70.76 1.05
CL (L/h) 17.08 15.43 0.90 23.14 24.36 0.95
Vd (L) 53.81 53.11 0.99 61.50 62.75 0.98
Cmax (mg/L) 33.4 45.35 1.36 47.95 46.56 1.03
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mg/L in non-pregnant women and in the first, second, and 
third trimester of pregnancy, respectively (Fig. 5a).
Both the fraction (expressed as fraction of molar dose) 
of acetaminophen metabolized to NAPQI and the molar 
AUC ratio NAPQI/acetaminophen were used as measures 
for hepatotoxicity. The fractions and IQRs of acetaminophen 
converted to its metabolites, expressed on a molar basis, are 
illustrated in Fig. 5b. The dose fraction of acetaminophen 
metabolized to glucuronide was considerably increased in 
the second and third trimester (Table 4). On the basis of a 
Fig. 5  a Boxplot of the simu-
lated average concentration at 
steady state (Css,avg; y-axis) val-
ues for a dose of acetaminophen 
1000 mg administered orally 
to a non-pregnant and different 
pregnant populations discre-
tized in trimesters (n = 2000). 
The box is the interquartile 
range (IQR) representing the 
range between the 25th and 
75th percentile. The whiskers 
indicate 1.5 times the IQR. The 
line within the boxes indicates 
the generally accepted analgesic 
target concentration of 10 mg/L 
[24]. b Barplot of the predicted 
median and IQR fractions 
of metabolite formation to 
acetaminophen (expressed as 
percentage of molar acetami-
nophen dose) for non-pregnant 
and different pregnant popula-
tions discretized in trimesters 
(n = 2000). NAPQI N-acetyl-
p-benzoquinone imine
Table 4  Fraction, expressed as percentage of total paracetamol (molar) dose, of acetaminophen to metabolites
Data are reported as median [interquartile range]
NAPQI N-acetyl-p-benzoquinone imine
Population Unchanged acetami-
nophen excreted in urine
Acetaminophen glucuronide Acetaminophen sulfate NAPQI
Non-pregnant women 7.38 [0.13–13.46] 53.81 [51.16–57.19] 31.10 [28.98–33.32] 7.71 [6.40–9.35]
First trimester pregnant women 8.62 [0.85–15.15] 56.15 [53.41–59.59] 24.20 [22.29–26.20] 11.03 [9.14–13.36]
Second trimester pregnant women 7.43 [0.80–13.34] 62.06 [59.32–65.09] 21.47 [19.86–23.14] 9.03 [7.48–10.98]
Third trimester pregnant women 7.16 [0.32–12.34] 63.91 [61.71–67.18] 20.65 [19.13–22.36] 8.23 [6.82–10.13]
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‘worse-case scenario’ (80% constant increase) pattern during 
pregnancy, the results suggest that the molar dose fraction 
of acetaminophen converted to NAPQI was highest during 
the first (median [IQR]: 11.0% [9.1–13.4%]) followed by 
the second (9.0% [7.5–11.0%]) and third trimester (8.2% 
[6.8–10.1%]), compared with non-pregnant women (7.7% 
[6.4–9.4%]), although a great inter-individual variability 
was observed, resulting in overlapping IQR between non-
pregnant and pregnant women (Table 4).
Molar AUC ratios of acetaminophen metabolites (glucu-
ronide, sulfate, and NAPQI) to acetaminophen are presented 
in Fig. 6. The median AUC ratio of acetaminophen sulfate to 
acetaminophen was lower in pregnancy than in non-pregnant 
women, with its nadir in the second trimester. The median 
AUC ratio of glucuronide to acetaminophen increased with 
advancing gestation. The median AUC ratio of NAPQI was 
highest during the first trimester followed by the second and 
third trimester. These findings suggest higher NAPQI for-
mation in pregnant women than in non-pregnant women, 
especially during the first trimester.
4  Discussion
The many pregnancy PBPK models developed to assess 
the impact of pregnancy on pharmacokinetics have mainly 
focused on drugs that are eliminated via unchanged renal 
excretion or metabolism by phase I (CYP) pathways. Little 
attention has been paid to drugs metabolized by phase II 
enzymes. Although acetaminophen is one of the most fre-
quently used drugs throughout pregnancy, little is known 
about the achieved Css,avg and the potential risk of hepatotox-
icity at different stages of pregnancy at therapeutic dosages.
The developed pregnancy PBPK models could adequately 
predict the pharmacokinetics of acetaminophen throughout 
pregnancy. Based on these developed PBPK models, it was 
illustrated that following therapeutic dosage of 1000 mg of 
acetaminophen, the lowest Css,avg values were achieved in the 
third trimester (median [IQR]: 4.5 [3.8–5.1] mg/L), followed 
by the second trimester, first trimester, and non-pregnant 
state with Css,avg levels of 4.9 [4.1–5.5], 5.6 [4.6–6.3], and 
6.7 [5.9–7.4] mg/L, respectively. Conversely, the molar dose 
fraction of acetaminophen converted to NAPQI was high-
est during the first (median [IQR]: 11.0% [9.1–13.4%]), fol-
lowed by the second (9.0% [7.5–11.0%]) and third trimester 
(8.2% [6.8–10.1%]), compared with that simulated in non-
pregnant women (7.7% [6.4–9.4%]). However, it has to be 
noted that a great inter-individual variability was observed, 
resulting in an overlapping IQR of NAPQI between non-
pregnant and pregnant women (Table 4). The molar AUC 
ratio NAPQI/acetaminophen was highest during the first 
trimester and decreased in the second and third trimester. 
This decrease in NAPQI production can be explained by 
the fact that, as UGT1A1 activity increases, a higher molar 
fraction of acetaminophen is being glucuronidated, leaving 
less substrate available for oxidation via CYP2E1 (assum-
ing a ‘worst-case scenario’ with an 80% constant increase). 
Our findings suggest that acetaminophen exposure is likely 
to be lower in pregnant than in non-pregnant women, and is 
related to pregnancy duration. Despite these findings, dose 
adjustments cannot be advised yet, as toxicity related to 
more NAPQI production during pregnancy compared with 
Fig. 6  Predicted area under 
the plasma concentration–time 
curve (AUC) from time zero 
to 6 h (AUC 0-6h) metabolite 
to acetaminophen ratios of 
N-acetyl-p-benzoquinone imine 
(NAPQI) (a), acetaminophen 
sulfate (b), and acetaminophen 
glucuronide (c) in non-pregnant 
women and women at the first, 
second, and third trimester of 
pregnancy
PBPK Modeling of Acetaminophen in Non-pregnant and Pregnant Women
non-pregnant women may occur. Information on glutathione 
abundance during pregnancy and NAPQI in vivo data are 
required to further refine the presented model. Quantitative 
information on gestation-specific changes in enzyme activity 
available in literature was incorporated in the model. The 
main caveat of such a knowledge-driven approach is the 
available amount and quality of the information in the scien-
tific literature. If these are insufficient, biologically plausible 
assumptions must be made. Previously, well-validated PBPK 
models have been developed of acetaminophen in other 
special populations [25–27]. Although these models could 
be used to further validate the predictions of both acetami-
nophen and its metabolites throughout different stages of 
pregnancy once adequate clinical data are available, those 
models were not used here as, for example, it was unknown 
whether pregnancy itself changes the levels of the co-factors 
for acetaminophen glucuronidation and sulfation. Sparse 
information was available on pregnancy-induced changes 
in UGT1A1 activity, which hampers an accurate and con-
tinuous description of these changes in the pregnancy PBPK 
model. Therefore, these changes in the presented pregnancy 
PBPK model were informed by reported reductions in the 
mean serum concentrations of free bilirubin in the first, sec-
ond, and third trimester of pregnancy [16]. While bilirubin 
is an exclusive substrate of UGT1A1 [15], the mean serum 
concentration may not accurately represent underlying 
changes in clearance. For example, it is unknown if biliru-
bin production during pregnancy is different. Therefore, it 
has not been taken into account. Interestingly, UGT1A1-
mediated clearance was slightly overestimated in the pre-
sented PBPK models, suggesting that factors other than an 
increase in clearance, at least partly, may contribute to the 
observed reductions in free bilirubin serum concentrations. 
One potential factor is the metabolism of acetaminophen 
through UGTs other than only UGT1A1 (as implemented in 
this PBPK model). However, limited evidence is available 
on which other UGTs contribute to acetaminophen metab-
olism and the fractions metabolized via different UGTs. 
While UGT1A6 and UGT1A9 have been suggested to play 
an important role in acetaminophen metabolism [28, 29], 
no quantitative information can currently be generated from 
available data. Moreover, high inter-individual variability in 
acetaminophen glucuronidation, partly caused by polymor-
phism, may hamper the prediction of metabolism in humans. 
Finally, discrete changes do not capture the full dynamics of 
changes in biological systems (such as the increase in gene 
expression) and a continuous description of UGT1A1 activ-
ity changes during pregnancy may be more accurate. Yet, a 
clear lack of data prevented a finer resolution of UGT1A1 
activity changes. Additionally, it should also be assessed 
whether upregulation of UGT1A1 is tissue specific and how 
that translates into in vivo pharmacokinetics. Further in vitro 
or in vivo studies addressing this issue are clearly needed.
Although a very small dose fraction of acetaminophen 
is eliminated by CYP2E1, accurate characterization of 
this pathway is crucial since it is involved in hepatotoxic-
ity. However, conflicting and limited data are available on 
changes in CYP2E1 enzyme expression throughout human 
pregnancy. Lee et al. [19] reported that CYP2E1 gene expres-
sion in female hepatocytes is induced by human placental 
lactogen (hPL; human chorionic somatomammotropin). 
Plasma concentrations of hPL increase progressively dur-
ing pregnancy, with Cmax values of 5–7 mg/L being reached 
near term. The CYP2E1 induction by hPL was concentra-
tion dependent, yet the hPL concentration exhibiting 50% of 
the maximal induction could not be estimated because the 
effect did not reach a plateau [19]. To determine whether 
the increased CYP2E1 messenger RNA (mRNA) levels led 
to a corresponding increase in protein expression in human 
hepatocytes, enzymatic activity protein and metabolic activ-
ity of CYP2E1 were analyzed by using western blot and 
the CYP2E1 probe drug chlorzoxazone, respectively. The 
formation of 6-hydroxychlorzoxazone was increased signifi-
cantly in the majority of hepatocytes pretreated with hPL. 
Taken together, these results indicate that, at physiologi-
cal concentrations reached during pregnancy, hPL induces 
CYP2E1 expression [19]. In another study, medroxyproges-
terone acetate increased CYP2E1 activity [20]. The activ-
ity increase was concentration dependent in the range of 
0–100 µmol/L; the highest level amounted to 170.8% of 
the control level observed at 50 µmol/L [20]. While it is 
difficult to extrapolate these in vitro findings to a quantita-
tive CYP2E1 activity change in vivo, the 80% increase in 
CYP2E1 activity reported in term pregnant women was used 
in the herein presented pregnancy PBPK models [21, 22]. 
Furthermore, although a lower value may be plausible at ear-
lier stages of pregnancy, an 80% induction was used because 
this value translates into the maximum of NAPQI exposure 
that can probably be expected in vivo, if a monotonous 
increase in CYP2E1 activity during pregnancy is assumed, 
thereby constituting a ‘worst-case scenario’. Additional sce-
narios of different CYP2E1 induction patterns in the first 
trimester have been assessed in a sensitivity analysis given 
in the Electronic Supplementary Material. As the objective 
of the present study was to address maternal exposure to 
acetaminophen and its metabolites, fetal NAPQI exposure 
was not modeled here, which is clearly of great interest. 
Although technically feasible, such consideration is out of 
the scope and should be further investigated.
Due to missing literature information on the glutathione-
S-transferase enzyme, it was assumed that glutathione tissue 
concentrations in pregnant women are similar to those in 
non-pregnant subjects. However, if glutathione-S-transferase 
activities are lower in pregnant women, NAPQI concen-
trations can be expected to be even higher. If this is not 
explicitly taken into consideration, the model presented here 
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would predict a too low increase in the generated NAPQI 
amount, bearing the potential of falsely inferring that there 
is no substantially increased risk of hepatotoxicity. While the 
incorporation of explicit NAPQI detoxification kinetics and 
changes in glutathione-S-transferase expression are beyond 
the scope of this study, they should be carefully examined 
before any dose recommendations are inferred from the 
model predictions.
The pregnancy PBPK models were used to investigate 
acetaminophen pharmacokinetics throughout pregnancy 
after a therapeutic dosage (1000 mg). The Css,avg of aceta-
minophen and NAPQI exposure, was a marker for efficacy 
and potential hepatotoxicity, respectively, to non-pregnant 
women. In this study, Css,avg was chosen as it is a widely used 
measure to express the efficacy of acetaminophen [24]. It 
should be noted that the Css,avg (i.e., a pharmacokinetic tar-
get) might not be completely the same as effective analgesia 
(pharmacodynamic). It is unknown if the pharmacodynamic 
target changes throughout pregnancy. Using the pharmacoki-
netic target as a meaningful measure, the results revealed 
that throughout all stages, for both non-pregnant as well 
as pregnant women, Css,avg is not reached, with the lowest 
value during the third trimester. The question arises if this 
is the correct target concentration for non-pregnant adults, 
as in older people (whose volume of distribution and clear-
ance are lower than those in young healthy adults) a target 
concentration of 10 mg/L is reached [30]. Further research 
should therefore focus on which Css,avg should be achieved 
for effective pain relief throughout different stages of preg-
nancy, taking safety into account. As emphasized before, 
investigations into NAPQI formation during different stages 
of pregnancy need to be combined with an assessment of the 
changes of the detoxifying capacity (e.g., glutathione lev-
els) of non-pregnant and pregnant women to determine the 
optimal dose of acetaminophen throughout these different 
stages of pregnancy. Future research should not only focus 
on in vitro and in vivo studies related to UGT and CYP2E1 
expression throughout pregnancy, but also on qualification 
of these model predictions in relation to NAPQI/oxidative 
metabolite concentrations.
5  Conclusion
The developed pregnancy PBPK models successfully pre-
dicted pharmacokinetics of paracetamol and its metabolites 
at different stages of pregnancy. Predictions resulted in the 
lowest Css,avg in the third trimester, followed by increased 
number of weeks of gestational age and non-pregnant state. 
Conversely, the molar dose fraction of acetaminophen 
metabolized to NAPQI was highest during the first trimester, 
followed by the second trimester, third trimester, and non-
pregnant women. AUC ratio NAPQI/acetaminophen was 
highest during the first, followed by the second and third 
trimester. Although it has to be noted that a great inter-indi-
vidual variability was observed, resulting in an overlapping 
IQR of NAPQI between non-pregnant and pregnant women, 
these findings suggest that acetaminophen exposure is, on 
average, likely to be lower in pregnant than in non-pregnant 
women and that this reduction may be related to pregnancy 
duration. Despite these findings, dose adjustments cannot be 
advised yet, as toxicity related to more NAPQI production 
during pregnancy than in non-pregnant women may occur. 
Information on glutathione abundance during pregnancy 
and NAPQI in vivo data are required to further refine the 
presented model.
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